Abstract:Oncology immunotherapy has gained significant advances in recent years and benefits cancer patients with superior efficacy and superior clinical responses. Currently over ten immune checkpoint antibodies targeting CTLA-4 and PD-1/PD-L1 have received regulatory approval worldwide and over thousands are under active clinical trials. However, compared to the rapid advance of Monoclonal Antibody (mAb), studies on immunotherapeutic small molecules have far lagged behind. Small molecule immunotherapy not only can target immunosuppressive mechanisms similar to mAbs, but also can stimulate intracellular pathways downstream of checkpoint proteins in innate or adaptive immune cells that mAbs are unable to access. Therefore, small molecule immunotherapy can provide an alternative treatment modality either alone or complementary to or synergistic with extracellular checkpoint mAbs to address low clinical response and drug resistance. Fortunately, remarkable progress has achieved recently in the pursuit of small molecule immunotherapy. This review intends to provide a timely highlight on those clinically investigated small molecules targeting PD-1/PD-L1, IDO1, and STING. The most advanced IDO1 inhibitor epacadostat have been aggressively progressed into multiple clinical testings. Small molecule PD-1/PD-L1 inhibitors and STING activators are still in a premature state and their decisive application needs to wait for the ongoing clinical outcomes. Since no small molecule immunotherapy has been approved yet, the future research should continue to focus on discovery of novel small molecules with distinct chemo-types and higher potency, identification of biomarkers to precisely stratify patients, as well as validation of many other immune-therapeutic targets, such as LAG3, KIRs, TIM-3, VISTA, B7-H3, and TIGIT.

Recent Advances of Small Molecular Regulators Targeting G Protein- Coupled Receptors Family for Oncology Immunotherapy.

Genetically engineered T cells for cancer immunotherapy

Recent advances in small molecule based cancer immunotherapy

Small-molecule agents for cancer immunotherapy

Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities

Targeting G Protein–Coupled Receptors in Immuno-Oncological Therapies

Small-Molecule Immuno-Oncology Therapy: Advances, Challenges and New Directions.

Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy

Targeting PD-1/PD-L1 in tumor immunotherapy: Mechanisms and interactions with host growth regulatory pathways

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

PD-1/PD-L1 Inhibitors for Immuno-oncology: from Antibodies to Small Molecules

Emerging therapeutic frontiers in cancer: insights into posttranslational modifications of PD-1/PD-L1 and regulatory pathways

Small Molecules As PD-1/PD-L1 Pathway Modulators for Cancer Immunotherapy

Emerging immunological strategies: recent advances and future directions

Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway

A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints

Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts

Recent progress in targeting the sialylated glycan-SIGLEC axis in cancer immunotherapy

Regulation of post-translational modification of PD-L1 and associated opportunities for novel small-molecule therapeutics

Small-molecule Modulators of Tumor Immune Microenvironment

Generation, secretion and degradation of cancer immunotherapy target PD-L1